Influence of orphenadrine upon the protective activity of various antiepileptic s in the maximal electroshock-induced convulsions in mice

Pharmacological Reports

Volumn 61, Issue 4, 2009, Pages 732-736

  Czuczwar, Mirosław ^a   Ciȩszczyk, Jacek ^a   Czuczwar, Katarzyna ^a   Kiś, Jacek ^a   Saran, Tomasz ^b   Turski, Waldemar A ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Antiepileptic drugs; Maximal electroshock; Orphenadrine; Seizures

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; LAMOTRIGINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; ORPHENADRINE; OXCARBAZEPINE; PHENCYCLIDINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BINDING SITE; CONTROLLED STUDY; CONVULSION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; ELECTRIC SHOCK; MOUSE; NONHUMAN; SEIZURE; SEIZURE THRESHOLD;

EID: 70549100017     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(09)70127-6     Document Type: Article

References (23)

1. Borowicz KK, Kleinrok Z, Czuczwar SJ: Influence of D(-)CPP and (±)CPP upon the protective action of conventional antiepileptic drugs against electroconvulsions in mice. Pol J Pharmacol, 2000, 52, 431-439. (Pubitemid 32045906)
2. Brocks DR: Anticholinergic drugs used in Parkinson's disease: an overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharmacol Sci, 1999, 2, 39-46.
3. Cherkin DC, Wheeler KJ, Barlow W, Deyo RA: Medication use for low back pain in primary care. Spine, 1998, 23, 607-614. (Pubitemid 28154975)
4. Czuczwar SJ, Turski L, Schwarz M, Turski WA, Kleinrok Z: Effects of excitatory amino-acid antagonists on the anticonvulsive action of phenobarbital or diphenylhydantoin in mice. Eur J Pharmacol, 1984, 100, 357-362. (Pubitemid 14101705)
5. Gold RH: Orphenadrine citrate: Sedative or muscle relaxant? Clin Ther, 197, 1, 451-453.
6. 1 receptor antagonists on maximal electroshock seizure in infant rats. Biol Pharm Bull, 2007, 30, 477-480. (Pubitemid 46355928)
7. Kamei C, Ishizawa K, Kakinoki H, Fukunaga M: Histaminergic mechanisms in amygdaloid-kindled seizures in rats. Epilepsy Res, 1998, 30, 187-194. (Pubitemid 28273383)
8. Kornhuber J, Parsons CG, Hartmann S, Retz W, Kamolz S, Thome J, Riederer P: Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. J Neural Transm Gen Sect, 1995, 102, 237-246. (Pubitemid 3018744)
9. Latta D, Turner E: An alternative to quinine in nocturnal leg cramps. Curr Ther Res Clin Exp, 1989, 45, 833-837. (Pubitemid 19138601)
10. Lees A: Alternatives to levodopa in the initial treatment of Elary Parkinson's disease. Drugs Aging, 2005, 22, 731-740. (Pubitemid 41242117)
11. Litchfield JT, Wilcoxon F: A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther, 1949, 96, 99-113.
12. Luzza F, Raffa S, Saporito F, Oreto G: Torsades de pointes in congenital long QT syndrome following low-dose orphenadrine. Int J Clin Pract, 2006, 60, 606-608.
13. Nicholson KL, Balster RL. Evaluation of the phencyclidine-like discriminative stimulus effects of novel NMDA channel blockers in rats: Psychopharmacology (Berl), 2003, 170, 215-224.
14. Pubill D, Verdaguer E, Canudas AM, Sureda FX, Escubedo E, Camarasa J, Pallàs M, Camins A: Orphenadrine prevents 3-nitropropionic acid-induced neurotoxicity in vitro and in vivo. Br J Pharmacol, 2001, 132, 693-702.
15. Roozemond RC, Hespe W and Nauta WT: The concentrations of orphenadrine and its N-demethylated derivatives in rat brain, after intraperitoneal administration of orphenadrine and tofenacine. Int J Neuropharmacol, 1968, 7, 293-300.
16. Scholz EP, Konrad FM, Weiss DL, Zitron E, Kiesecker C, Bloehs R, Kulzer M et al.: Anticholinergic antiparkinson drug orphenadrine inhibits HERG channels: block attenuation by mutations of the pore residues Y652 or F656. Naunyn Schmiedebergs Arch Pharmacol, 2007, 376, 275-284. (Pubitemid 350164544)
17. Sureda FX, Gabriel C, Pallas M, Adan J, Martinez JM, Escubedo E, Camarasa J, Camins A: In vitro and in vivo protective effect of orphenadrine on glutamate neurotoxicity. Neuropharmacology, 1999, 38, 671-677.
18. Świa̧der M, Chwalczuk K, Wielosz M, Czuczwar SJ: Influence of chronic treatment with H1 receptor antagonists on the anticonvulsant activity of antiepileptic drugs. Pol J Pharmacol, 2001, 53, 93-96. (Pubitemid 32288345)
19. Troupin AS, Mendius JR, Cheng F, Risinger MW: MK-801. In: New Anticonvulsant Drugs. Eds. Meldrum BS, Porter RJ, John Libbey, London, Paris, 1986, 191-201.
20. Tomczyk T, Haberek G, Zuchora B, Jarosławska-Zych A, Kowalczyk MS, Wielosz M, Urbańska EM: Enhanced glutamatergic transmission reduces the anticonvulsant potential of lamotrigine but not of felbamate against tonic-clonic seizures. Pharmacol Rep 2007, 59, 462-466. (Pubitemid 47554827)
21. Urbanska EM, Czuczwar SJ, Kleinrok Z, Turski WA: Excitatory amino acids in epilepsy. Rest Neurol Neurosci, 1998, 13, 25-39.
22. Urbanska EM, Dziki M, Kleinrok Z, Czuczwar SJ, Turski WA: Influence of MK-801 on the anticonvulsant activity of antiepileptics. Eur J Pharmacol, 1991, 200, 277-282.
23. Valtonen EJ: A controlled clinical trial of chlormezanone, orphenadrine, orphenadrine/paracetamol and placebo in the treatment of painful skeletal muscle spasms. Ann Clin Res, 1975, 7, 85-88.